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Abstract 
Background: We have previously reported the design, pharmacological properties and imaging application of brad‑
ykinin (BK) B2 receptor (B2R) ligands conjugated with fluorophores such as fluorescein derivatives at their N‑terminus. 
To take advantage of the high penetration of infrared light into living tissues and their low autofluorescence in this 
region of the spectrum, additional probes conjugated with cyanine dye 7 (Cy7) were synthesized and characterized.
Results: The antagonist B‑9430 (D‑Arg‑[Hyp3,Igl5,D‑Igl7,Oic8]‑BK) and the agonist B‑9972 (D‑Arg‑[Hyp3,Igl5,Oic7,Igl8]‑
BK) were N‑terminally extended with the infrared fluorophore Cy7, producing the peptides B‑10665 and B‑10666, 
respectively. Pharmacological studies indicated that the agonist B‑10666 lost much affinity for the B2R vs. the parent 
peptide, whereas the antagonist B‑10665 better retained its potency vs. B‑9430 (competition of [3H]BK binding to 
human B2R, contractility of the human isolated umbilical vein for which potency losses were more important in each 
case). Both probes stained HEK 293 cells that expressed the B2R‑green fluorescent protein (GFP) construction in a spe‑
cific manner (confocal microscopy) and with very extensive co‑localization of the green and infrared fluorescence in 
either case. The agonist B‑10666 at 100 nM promoted the endocytosis of B2R‑GFP in live cells, but not the antagonist 
version at 10–25 nM. The Cy7‑labeled peptides did not label cells expressing the β2‑adrenoceptor‑GFP construction. 
B‑10665 at low nanomolar concentrations was an effective probe for the recombinant B2Rs in cytofluorometry and 
macroscopic imaging of cell wells (IVIS imaging system operated for infrared fluorescence detection).
Conclusions: Despite a propensity for non‑specific binding when used at high concentrations and limited sensitivity, 
Cy7‑conjugated peptidase‑resistant B2R ligands support original imaging and cytofluorometric applications.
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Background
We have previously reported the design, pharmacologi-
cal properties and imaging application of bradykinin (BK) 
B2 receptor (B2R) ligands conjugated with fluorophores 
such as fluorescein derivatives or AlexaFluor-350 at their 
N-terminus, with application to microscopy in cells that 
expressed recombinant receptors and their molecular 
partners such as arrestins, angiotensin converting 
enzyme and Rab small GTPases [1–4].
To take advantage of the high penetration of infrared 
light into living tissues and their low autofluorescence in 
this region of the spectrum, we wished to produce and 
characterize additional probes conjugated with a suitable 
fluorophore, cyanine dye 7 (Cy7). The parent peptides 
for the antagonist and the agonist versions are B-9430 
(D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-BK) and B-9972 (D-Arg-
[Hyp3,Igl5,Oic7,Igl8]-BK), respectively. They are well 
characterized pharmacologically [5]. The major kinin-
inactivating ectopeptidases are angiotensin converting 
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enzyme and aminopeptidase P [6, 7] and both parent 
peptides are intrinsically resistant to them due to exten-
sive substitutions with non-natural amino acid residues 
(Table  1). Thus, the Cy7-conjugated versions, termed 
B-10665 and B-10666, respectively, were produced, phar-




Trifluoroacetate salts of B-9430 and B-9972 (18.0  mg, 
0.01 mmol) were mixed respectively in 2.5 mL DMF with 
Cy7-NHS ester (6.82 mg, 0.01 mmol; CAS: 1432010-64-1; 
C41H48N3O4·Cl; Lumiprobe Corp., Hallandale Beach, FL, 
USA), HOBt (1.51  mg, 0.01  mmol) and DIEA (13.1  µL; 
0.075  mmol) at room temperature for 10  h (Addi-
tional file 1: Figure S1). The Cy7-BK conjugates, termed 
B-10665 and B-10666, respectively, were purified by pre-
parative HPLC on a Vydac C18 column using a gradi-
ent of 20–65 % acetonitrile/water containing 0.1 % TFA 
(Additional file 1: Figure S2, shows an example of a HPLC 
trace, that of B-10665). Their identities were confirmed 
by LC–MS (Additional file  1: Figure S3). The solubility 
of Cy7-conjugated peptides in aqueous media was much 
inferior to that of the parent peptides, and stock solutions 
were made in DMSO. The final DMSO concentration 
in pharmacological experiments was always inferior to 
0.1 % (v/v). BK was purchased from Bachem (Torrance, 
CA, USA) and the B2R antagonist icatibant, from Phoe-
nix Pharmaceuticals (Burlingame, CA, USA).
Radioligand binding assay
The binding of [3H]BK ([2,3-prolyl-3,4-3H(N)]-brady-
kinin, 85.4  Ci/mmol, PerkinElmer, Boston, MA, USA) 
to adherent intact cells expressing a form of the B2R was 
evaluated precisely as described [8]. HEK 293a cells sta-
bly expressing myc-tagged human B2Rs [8] were used to 
estimate receptor affinity via the binding competition of 
a fixed concentration of the radioligand (3 nM) with sev-
eral unlabeled peptides applied in a wide concentration 
range.
Contractility assays
Local ethics review boards approved the anonymous 
use of segments of human umbilical cords obtained fol-
lowing elective cesarean sections; informed consent was 
obtained from the mothers. Novel Cy-7 conjugated B2R 
ligands were assayed via the contraction of the human 
isolated umbilical vein [9, 10]. Cumulative concentration 
effect curves were constructed for the agonist version 
and its potency compared to that of BK. The antagonist 
version was introduced 30 min before the construction of 
the concentration-effect curves of the reference agonist 
BK and the shift to the right was used to determine their 
potencies using the Schild regression and pA2 scale [1].
Cytofluorometry
A subclone of HEK 293 cells, called HEK 293a, originally 
obtained from Sigma-Aldrich was used in these experi-
ments, either as a non-transfected cell type or as one 
stably expressing myc-tagged human B2Rs [8]. These 
cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10  % fetal bovine serum, 1  % l-glu-
tamine, and 1 % penicillin–streptomycin stock solutions 
(100×). Cells were detached using the protease-free Cell 
Dissociation Buffer (Invitrogen), incubated in D-MEM 
without serum at 37 °C for 30 min under agitation in the 
presence of a Cy7-conjugated ligands and other drugs, 
rapidly centrifuged (30  s, 11,000g) and resuspended in 
phosphate buffered saline. Then, the fluorescence of the 
cell suspensions was assessed using the BD SORP LSR II 
cell analyzer for the uptake of the as a function of stimu-
lation and transgene expression. The cytofluorometry 
results were analyzed using the BD FACS DIVA software.
Table 1 Sequences of novel BK analogs with N-terminal extensions compared to that of parent peptides in each category 
(italicized names)
Cy7, cyanine dye 7; Hyp, trans-4-hydroxyproline; Igl, α-(2-indanyl)glycine; Oic, (3as, 7as)-octahydroindole-2-carboxylic acid; Tic, 1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid
Peptide Position Binding competition  
IC50 nM (95 % C.L.)−1 0 1 2 3 4 5 6 7 8 9
B2 receptor agonists
 First parent peptide: BK Arg Pro Pro Gly Phe Ser Pro Phe Arg‑COOH 8.2 (6.0–11.2)
 Second parent peptide: B‑9972 D‑Arg Arg Pro Hyp Gly Igl Ser Oic Igl Arg‑COOH 17.3 (13.3–22.4)
 B‑10666 = Cy7‑B‑9972 Cy7 D‑Arg Arg Pro Hyp Gly Igl Ser Oic Igl Arg‑COOH 598 (481–742)
B2 receptor antagonists
 Parent peptide: B‑9430 D‑Arg Arg Pro Hyp Gly Igl Ser D‑Igl Oic Arg‑COOH 42.6 (20.0–90.8)
 B‑10665 = Cy7‑B‑9430 Cy7 D‑Arg Arg Pro Hyp Gly Igl Ser D‑Igl Oic Arg‑COOH 25.7 (11.5–57.1)
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Microscopy
HEK 293 cells, either not transfected or stably express-
ing a fully functional rabbit B2R construction fused 
to green fluorescent protein (B2R-GFP) [2, 11] were 
grown as described and plated on poly-l-lysine pre-
coated glass surfaces. B2R-GFP is a high affinity, fully 
functional receptor that supports subcellular localiza-
tion in intact cells; further, the fusion protein is not 
degraded by short treatments with various ligands 
(immunoblot evidence) [5] and is not expected to 
participate to any energy transfer with Cy7-labeled 
ligands. As a specificity control, other HEK 293 cells 
were transiently transfected with a vector coding for 
the β2-adrenoceptor-GFP Topaz fusion protein [12] 
(the vector is a generous gift from Prof. Michel Bou-
vier, Université de Montréal) using polyethylenimine 
as described [13]. Cells were generally treated for 
30  min with Cy7-conjugated ligands (incubation car-
ried out at 37  °C in humidified atmosphere containing 
5  % CO2), rinsed 4–5 times with phosphate buffered 
saline, observed in microscopy for green and infrared 
epifluorescence and differential interference contrast 
microscopy (DIC) using a Quorum Wave FX confo-
cal spinning disk microscope coupled to a Hamamatsu 
ImageEM digital camera (filters for GFP: excitation 
491 nm, emission 536 nm; for Cy7: excitation 642 nm, 
emission 810). The objective was Leica HCX PL APO 
63X/1,30 glycerol immersion lens.
Imaging of infrared fluorescence in macroscopic objects
The integrated imaging station IVIS Lumina LT Series III 
(PerkinElmer), along with its Living Image software, was 
exploited to evaluate the distribution of B2Rs in macro-
scopic object using the intrinsic infrared fluorescence of 
the antagonist B-10665. The apparatus was set in fluo-
rescence mode with filters at 675  nm (excitation) and 
831  nm (emission), medium binning and 60  s exposure 
time. This experiment exploited HEK 293a cells grown in 
24-well plates that stably expressed either human or rat 
B2R sequences N-terminally tagged with the myc epitope 
[8]. Expression of these receptors as a function of phar-
macologic treatment was controlled in separate plates 
of cells that were not fixed or permeabilized using the 
binding of anti-myc monoclonal antibody (clone 4A6, 
Millipore, dilution 1:1000) added along goat horseradish 
peroxidase-conjugated anti-mouse IgG antibodies (Santa 
Cruz, dilution 1:1000). After 15  min of incubation at 
37 °C and 4 washing with phosphate buffered saline, the 
reaction was revealed by adding the TrueBlue substrate 
for immunohistochemistry (Kirkegaard & Perry Lab, Inc., 
Gaithersburg, MD, USA) used as directed. The resulting 
blue precipitate was photographed at the macroscopic 
scale.
Data analysis
Results are presented as mean ± SEM. Radioligand bind-
ing data were fitted by nonlinear regression to a one-site 
competition equation using a least-square method (Prism 
5.0, GraphPad Software Inc., San Diego, CA, USA) and 
IC50 values with their 95  % confidence limits were cal-
culated from this procedure. The same computer pro-
gram was used to draw concentration-effect curves (least 
square fitting of sigmoidal dose–response equation with 
variable slope) and to derive contractile EC50 values.
Results
Pharmacology of Cy7‑conjugated bradykinin analogs
A radioligand binding assay was conducted to evaluate 
the affinity of the novel fluorescent putative B2R ligands 
(Fig. 1, IC50 values and 95 % confidence limits in Table 1). 
Unlabeled BK itself displaced the specific binding of [3H]
BK (3 nM) to stably expressed human recombinant B2Rs 
with a nanomolar potency. The full agonist B-9972, that 
incorporated several non-natural amino acid residues 
(Table  1), loses  ~twofold affinity for the receptor, remi-
niscent of the order of potency at the rabbit B2R [2]. The 
Cy7 conjugate of B-9972, termed B-10666, exhibits an 
important ~35-fold loss of affinity vs. the parent peptide 
B-9972, also typical of N-prolonged agonists [8]. How-
ever, the Cy7-conjugated form of the antagonist B-9430, 
termed B-10665, is about equipotent to its parent peptide 
(Fig. 1; Table 1).
The human umbilical vein is a contractile bioassay for 
the endogenous B2R, and was exploited to further study 
the pharmacology of Cy7-conjugated analogs (Fig.  2). 
The fluorescent peptide B-10666 was confirmed a B2R 
agonist, but with a massive 4240-fold loss of potency vs. 
BK based on an extrapolated concentration-effect for the 
hu myc-B2R (stable)

























Fig. 1 Competition of [3H]bradykinin (3 nM) binding to HEK 293a 
cells stably expressing human myc‑B2R by bradykinin (BK) homologs. 
Values are the means ± SEM. of the number of duplicate determina‑
tions indicated by n. Average specific binding without competitor 
(100 %) averaged 133.8 fmol/well. IC50 values are reported in Table 1
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former peptide (Fig. 2a). B-10665 has no direct effect on 
the isolated umbilical vein, but was a surmountable and 
rather potent antagonist of BK (Fig.  2b) with an esti-
mated pA2 of 6.83, but significantly less potent than the 
parent peptide B-9430 in this preparation (pA2 7.7) [5]. 
Thus, in this assay, the potency of both Cy7-conjugated 
peptides vs. their respective parent peptides was inferior 
to what could have been expected from the radioligand 
binding competition assay.
Applications based on the fluorescence of Cy7‑labeled B2R 
ligands: cytofluorometry
Binding of the antagonist B-10665 was detected using its 
intrinsic infrared fluorescence in detached, intact HEK 
293a cells that stably expressed human myc-tagged B2Rs 
(Fig. 3). The low autofluorescence of cells in the infrared 
range allowed detecting the binding of the probe at sub-
nanomolar concentrations. The binding was specific as 
shown by its very low intensity in non-transfected cells 
and its extensive competition by the non-fluorescent B2R 
antagonist icatibant in co-treated cells (Fig.  3). Higher 
concentrations of B-10665 produced a specific binding 
that plateaued in the low nanomolar range, as expected 
with cells expressing a finite number of receptors, but 
non-specific fluorescence (measured in the presence of 
icatibant) increased considerably more, possibly related 
to the lipophilic nature of the fluorophore (Additional 
file 1: Figure S4).
Microscopy
Adherent and intact cells that stably expressed the rabbit 
B2R-GFP construction exhibited the typical membrane-
associated green fluorescence corresponding to the rest-
ing receptor that was obviously absent in non-transfected 
HEK 293 cells (Fig. 4). There was no infrared fluorescence 
in resting cells, expressing or not B2R-GFP. The antago-
nist B-10665 (10 or 25  nM) labelled essentially plasma 
membranes in the infrared if and only if B2R-GFP was 
expressed; both signals co-localized. The plasma mem-
brane fluorescence of B-10665 (10 nM) was prevented in 
B2R-GFP-expressing cells that had been pretreated with 
the B2R antagonist icatibant (Fig. 4), supporting the com-
petition of the fluorescent antagonist receptor binding by 
the non-fluorescent antagonist.
The agonist B-10666 (100  nM) determined the endo-
cytosis of a fraction of the plasma membrane receptors 
and colocalized, in part, with B2R-GFP in cells (Fig. 5). At 
the used concentration, the agonist did not label untrans-
fected cells or icatibant-pretreated receptor-expressing 
cells, supporting a high specificity in cells that were vig-
orously rinsed before observation.
The comparable β2-adrenoceptor-GFP Topaz construc-
tion was used in additional control experiments. This 
fusion protein, when transiently expressed in HEK 293 
cells, is mainly expressed at the plasma membrane level 
but with scattered intracellular labeling more intense than 
that of stably expressed B2R-GFP (Additional file  1: Fig-
ure S5). β2-adrenoceptor-GFP Topaz is pharmacologically 
reactive, as shown in isoproterenol-stimulated cells: the 
receptors are then translocated into endosomes that are 
better differentiated from the cytosolic background fluo-
rescence at high magnification (Additional file  1: Figure 
S5). The agonist-induced endocytosis was prevented by a 
co-treatment with propranolol (Additional file  1: Figure 
S5), supporting the receptor identity. Both the C7-conju-
gated B2R ligands failed to label HEK 293 cells expressing 
β2-adrenoceptor-GFP Topaz (Additional file 1: Figure S6).
Imaging of infrared fluorescence in macroscopic objects
The fluorescence imaging system was used to probe the 
properties of the antagonist B-10665 in controlled con-
ditions were cell wells containing confluent HEK 293a 






















Pharmacology of Cy7-labeled peptides in  
the human umbilical vein 
agonist effect of B-10666










b antagonist effect of B-10665







B-10665 1 µM (6)
B-10655 10 µM (6)
[BK]  (M)
pA2
Fig. 2 Pharmacology of the Cy7‑labeled ligands in the human umbil‑
ical vein contractility assay. a Agonist effect of B‑10666 compared 
to that of BK. The maximal effect mediated by the endogenous B2Rs 
have been estimated by exposing tissues to a maximal concentration 
of BK. b Competitive antagonist effect of B‑10665 against BK‑induced 
contraction. Values are mean ± SEM of the number of replicates 
indicated by n
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(Fig.  6a). B-10665 stained the cell wells (from a 24-well 
plate) in a concentration-dependent manner (1–10 nM), 
more so for the rat construction. Non-transfected cells, 
used as controls, showed some non-specific signal when 
treated with 10  nM of the probe, but not at the 1  nM 
concentration level. The fluorescence essentially faded 
after a single 60-sec acquisition period (Fig. 6a, bottom). 
The expression of the myc-tagged receptors was verified 
by an immunohistochemistry technique based on anti-
myc antibodies applied to the same type of macroscopic 
object, a cell well plate (Fig.  6b). The blue labeling of 
receptor-expressing cell populations was more intense 
than the background staining, and the rat construction 
apparently more densely expressed than the human one. 
The pharmacological treatments had no obvious effect on 
the density of receptors. B-10665 (up to 250  nM) could 
not detect endogenous B2R presence in slices of human 
umbilical cord using this imaging system (data not 
shown), probably related to the low physiological density 
of the receptors.
HEK 293a cells stably expressing human myc-B2R 






Fig. 3 Cytofluorometric detection of B‑10665 (1 nM) in detached HEK 293a cells stably expressing human myc‑tagged B2Rs and competition of 
binding by the alternate antagonist icatibant. a Sample histograms for infrared fluorescence. Detached cells were treated for 30 min with B‑10665; 
icatibant was applied 15 min before B‑10665 when utilized. b Concentration‑effect relationship for cell labeling with B‑10665 and competition with 
icatibant in replicated experiments
Page 6 of 10Gera et al. BMC Res Notes  (2016) 9:452 
Discussion
The pair of Cy7-conjugated agonist/antagonist ligands 
of the B2R, B-10666 and B-10665, respectively, shared 
the same design as a previously reported pair based 
on the same parent peptides, fluorescein-5-thiocarba-
moyl (FTC)-B-9972 and FTC-B-9430 [4]. While the 
conjugation to a fluorophore produced a loss of receptor 
affinity for both sets of peptides, the Cy7-conjugated ago-
nist B-10666 was particularly poor, whereas FTC-B-9972 
fared better (EC50 108 nM in the umbilical vein contrac-
tility assay [4]). Despite this structure–activity idiosyn-























Fig. 4 Imaging of intact HEK 293 stably expressing or not B2R‑GFP based on the Cy7‑conjugated antagonist ligand B‑10665 (infrared fluorescence 
rendered as the red false color). All labelings were performed for 30 min at 37 °C, followed by rinsing. Original magnification 95×
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experiment where it showed the expected receptor-inter-
nalizing effect in cells incubated at 37  °C (Fig.  5). The 
pharmacology of the antagonist versions, B-10665 and 
FTC-B-9430, are very similar, with pA2 values of 6.83 and 
6.96, respectively, against BK-induced contractions in the 
umbilical vein and a good receptor affinity, based on the 
competition of [3H]BK binding to recombinant receptors. 
Either antagonist imaged B2Rs at the cell surface, without 
endocytosis (Fig. 4) [4].
The original properties of the studied Cy7-conjugated 
ligands included: (1) superior performance in co-local-
ization experiments with the B2R-GFP fusion protein 
(Figs.  4, 5), which was not possible with fluorescein-
labeled ligands, supporting the very extensive co-locali-
zation of ligands with the receptor at both the cell surface 
and, for the agonist version, in endosomes; (2) high sig-
nal/noise ratio of nanomolar levels of B-10665 in cyto-
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Fig. 5 Imaging of intact HEK 293 stably expressing or not B2R‑GFP based on the Cy7‑conjugated agonist ligand B‑10666 (100 nM). Presentation as 
in Fig. 4














































































Fig. 6 Imaging of the B2R distribution in a plate of wells containing HEK 293a cells that stably express myc‑tagged recombinant human or rat 
receptors (hu myc‑B2R, rt myc‑B2R, respectively) or non‑transfected cells (nt). a Infrared fluorescence following treatment with B‑10665 (30 min, 
37 °C, followed by ample rinsing). The color signal represents infrared fluorescence intensity, as quantified on the scale at the right hand side, and is 
overlayed on a black and white photograph of the object. Top fluorescence recorded during the first exposure (60 s); bottom results from the second 
exposure of the same object (60 s). b Detection of the receptors via immunohistochemistry of their myc tag (blue precipitate). The cell wells were 
submitted to the same treatments as in a. In both a and b, results are representative of 2 separate experiments
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the infrared (Fig. 3); (3) detection of B2R populations at 
the macroscopic scale with essentially no autofluores-
cence if high densities of receptors are observed, as in cell 
wells expressing recombinant B2Rs (Fig.  6); (4) inferred 
resistance to peptidases, which is relevant because cell 
surface ectopeptidase density may vastly exceed that of 
BK receptors in some cells, such as human endothelial 
cells [14]; (5) a propensity for non-specific binding that 
requires careful rinsing, possibly related to the hydropho-
bic nature of Cy7; (6) a rapid “bleaching” observed both 
in microscopy and with the macroscopic imaging system 
(Fig.  6), but FTC-conjugated ligands do not fare better 
in this respect; (7) a limitation in sensitivity, common 
to most or all fluorophores. Thus, recombinant recep-
tors expressed at high densities are best detected with 
B-10665.
Conclusions
Despite limited sensitivity and non-specific behavior at 
high concentrations (Additional file  1: Figure S4), Cy7-
conjugated peptidase-resistant B2R ligands support origi-
nal imaging applications, such as co-localization with the 
B2R-GFP construction, and cytofluorometry.
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